Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors

Jakob Siedlecki, Cheryl Fischer, Benedikt Schworm, Thomas C. Kreutzer, Nikolaus Luft, Karsten Kortuem, Ricarda G. Schumann, Armin Wolf, Siegfried PriglingerScientific 2020 · DOI

Abstract

Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD). To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat & extend anti-VEGF treatment, defined as nAMD expressing CNV exudation beyond the three monthly anti-VEGF loading doses by SRF only without any signs of exudative intra-retinal fluid (IRF) for ≥3 years. Incidence of macular atrophy and treatment responses were evaluated on multimodal imaging, including optical coherence tomography (OCT), blue autofluorescence (BAF) and near-infrared (NIR) confocal scanning laser ophthalmoscopy and fluorescence and indocyanine green angiography (FAG/ICGA). In total, 27 eyes (8.7%) of 26 patients with a mean follow-up of 4.2 ± 0.9 (3-5) years met the inclusion criteria. Mean age was 72 ± 6 (range: 61-86) years. The SRF only phenotype was seen from baseline in 14 eyes (52%), and in 13 eyes (48%) after a mean 1.0 ± 1.3 (1-3) injections. In years 1 to 5, mean 7.5, 5.9, 6.1, 6.1 and 7.0 anti-VEGF injections were given (p = 0.33). Cumulative macular atrophy incidence was 11.5% at year 1, 15.4% throughout years 2 to 4, and 22.4% at year 5. In conclusion, eyes manifesting activity by SRF only in treat & extend anti-VEGF regimen for nAMD seem to exhibit rather low rates of macular atrophy during long-term follow-up. SRF might be an indicator of a more benign form of nAMD.

Introduction

Neovascular age-related macular degeneration (nAMD) remains a leading cause of severe vision loss globally. While the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the management of exudative nAMD, long-term visual outcomes are often limited by the development of macular atrophy (MA). A critical area of debate in clinical practice is the management of retinal fluid. While intra-retinal fluid (IRF) is recognized as highly toxic to retinal tissues, the role of sub-retinal fluid (SRF) is more nuanced. Some evidence suggests that persistent SRF might actually serve a protective role, potentially providing trophic support to the outer retina or acting as a buffer against the toxic effects of choroidal neovascularization (CNV).

This study investigates the long-term (5-year) incidence of macular atrophy and functional outcomes in a specific subset of patients: those manifesting an "SRF-only" phenotype while under a Treat & Extend (T&E) anti-VEGF regimen.

Methods

Researchers conducted a retrospective cohort study at the Department of Ophthalmology, Ludwig-Maximilians-University Munich. A database of 310 eyes treated for nAMD was screened to identify eyes with a persistent SRF-only phenotype. Inclusion criteria required the presence of sub-foveal SRF and the complete absence of IRF for at least three years during treatment.

Atrophy was monitored using multimodal imaging, including Optical Coherence Tomography (OCT), Blue Autofluorescence (BAF), and Near-Infrared (NIR) imaging. This comprehensive approach allowed for the precise detection and tracking of atrophic lesions. The treatment followed a standard T&E protocol, where injection intervals were adjusted based on clinical and imaging signs of disease activity.

Results

Out of the initial cohort, 27 eyes (8.7%) met the strict criteria for the SRF-only phenotype. The mean follow-up duration was 4.2 years, with some patients followed for up to 5 years.

Incidence of Macular Atrophy

The study found a notably low cumulative incidence of macular atrophy. The incidence was 11.5% at Year 1, remained stable at 15.4% from Years 2 through 4, and reached 22.4% by Year 5. This rate is significantly lower than those reported in major clinical trials like CATT, which observed atrophy in 38% of eyes at five years.

Cumulative incidence of macular atrophy over 5 years of follow-up.

Visual Acuity and Treatment Burden

Functional outcomes were remarkably stable throughout the study period. Mean visual acuity improved significantly from 64.05 letters at baseline to 72.30 letters at Year 1 (p = 0.006). Crucially, this gain was maintained over the long term, with a mean of 72.22 letters at Year 5.

Mean visual acuity (ETDRS letters) showing significant initial gain and long-term stability.

The treatment burden remained consistent, with patients receiving an average of 7.5 injections in the first year and 7.0 in the fifth year (p = 0.33). This indicates that while the SRF-only phenotype requires ongoing management, it remains highly responsive to anti-VEGF therapy without requiring an escalating number of injections.

Discussion

The findings suggest that the SRF-only phenotype may represent a more benign variant of nAMD. The stability of visual acuity over five years is particularly encouraging, as many nAMD cohorts typically show a gradual decline in vision after the initial two years of treatment.

The topographic correlation observed—where atrophy occurred specifically at the site of the CNV lesion—supports the hypothesis that atrophy in these cases is a direct result of the underlying vascular lesion's toxicity rather than a generalized progression of "dry" AMD. The presence of SRF might mitigate this toxicity or indicate a less aggressive lesion type.

Limitations

The primary limitation of this study is the small sample size (n=27), which resulted from the highly specific inclusion criteria. Additionally, as a retrospective study, it lacks a direct control group of "completely dry" eyes within the same clinical setting for comparison.

Conclusion

Eyes manifesting nAMD activity solely through SRF under a Treat & Extend anti-VEGF regimen exhibit low rates of macular atrophy and maintain stable visual acuity over a five-year period. These results suggest that a more tolerant approach toward persistent SRF, provided IRF is absent, may be a viable and potentially protective strategy for long-term management of nAMD.

Summary updated

Abstract

Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD).To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat & extend anti-VEGF treatment, defined as nAMD expressing CNV exudation beyond the three monthly anti-VEGF loading doses by SRF only without any signs of exudative intra-retinal fluid (IRF) for ≥3 years. Incidence of macular atrophy and treatment responses were evaluated on multimodal imaging, including optical coherence tomography (OCT), blue autofluorescence (BAF) and near-infrared (NIR) confocal scanning laser ophthalmoscopy and fluorescence and indocyanine green angiography (FAG/ICGA). In total, 27 eyes (8.7%) of 26 patients with a mean follow-up of 4.2 ± 0.9 (3-5) years met the inclusion criteria. Mean age was 72 ± 6 (range: 61-86) years. The SRF only phenotype was seen from baseline in 14 eyes (52%), and in 13 eyes (48%) after a mean 1.0 ± 1.3 (1-3) injections. In years 1 to 5, mean 7.5, 5.9, 6.1, 6.1 and 7.0 anti-VEGF injections were given (p = 0.33). Cumulative macular atrophy incidence was 11.5% at year 1, 15.4% throughout years 2 to 4, and 22.4% at year 5. In conclusion, eyes manifesting activity by SRF only in treat & extend anti-VEGF regimen for nAMD seem to exhibit rather low rates of macular atrophy during long-term follow-up. SRF might be an indicator of a more benign form of nAMD.
BibTeX
@inproceedings{siedlecki2020impact,
  author = {Jakob Siedlecki and Cheryl Fischer and Benedikt Schworm and Thomas C. Kreutzer and Nikolaus Luft and Karsten Kortuem and Ricarda G. Schumann and Armin Wolf and Siegfried Priglinger},
  title = {{Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat \& Extend Anti-Vascular Endothelial Growth Factor Inhibitors}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-64901-9},
}
Figure